These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31055792)

  • 21. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
    Fleischmann R; van Adelsberg J; Lin Y; Castelar-Pinheiro GD; Brzezicki J; Hrycaj P; Graham NM; van Hoogstraten H; Bauer D; Burmester GR
    Arthritis Rheumatol; 2017 Feb; 69(2):277-290. PubMed ID: 27860410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population Pharmacokinetics of the TNF-α and IL-17A Dual-Variable Domain Antibody ABT-122 in Healthy Volunteers and Subjects With Psoriatic or Rheumatoid Arthritis: Analysis of Phase 1 and 2 Clinical Trials.
    Khatri A; Othman AA
    J Clin Pharmacol; 2018 Jun; 58(6):803-813. PubMed ID: 29364523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis.
    Jauslin P; Kulkarni P; Li H; Vatakuti S; Hussain A; Wenning L; Kerbusch T
    Clin Pharmacokinet; 2019 Aug; 58(8):1059-1068. PubMed ID: 30915660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis.
    Boyce EG; Rogan EL; Vyas D; Prasad N; Mai Y
    Ann Pharmacother; 2018 Aug; 52(8):780-791. PubMed ID: 29482351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.
    Gossec L; Strand V; Proudfoot C; Chen CI; Guillonneau S; Kimura T; van Hoogstraten H; Mangan E; Reaney M
    J Rheumatol; 2019 Oct; 46(10):1259-1267. PubMed ID: 30877216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.
    Genovese MC; van der Heijde D; Lin Y; St John G; Wang S; van Hoogstraten H; Gómez-Reino JJ; Kivitz A; Maldonado-Cocco JA; Seriolo B; Stanislav M; Burmester GR
    RMD Open; 2019; 5(2):e000887. PubMed ID: 31452928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
    Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1268-1280. PubMed ID: 31663465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.
    Ternant D; Ducourau E; Fuzibet P; Vignault C; Watier H; Lequerré T; Le Loët X; Vittecoq O; Goupille P; Mulleman D; Paintaud G
    Br J Clin Pharmacol; 2015 Feb; 79(2):286-97. PubMed ID: 25223394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials.
    Khatri A; Goss S; Jiang P; Mansikka H; Othman AA
    Clin Pharmacokinet; 2018 May; 57(5):613-623. PubMed ID: 28744796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
    Burmester GR; Strand V; Rubbert-Roth A; Amital H; Raskina T; Gómez-Centeno A; Pena-Rossi C; Gervitz L; Thangavelu K; St John G; Boklage S; Genovese MC
    RMD Open; 2019; 5(2):e001017. PubMed ID: 31673415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.
    Burmester GR; Lin Y; Patel R; van Adelsberg J; Mangan EK; Graham NM; van Hoogstraten H; Bauer D; Ignacio Vargas J; Lee EB
    Ann Rheum Dis; 2017 May; 76(5):840-847. PubMed ID: 27856432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab.
    Rubbert-Roth A; Furst DE; Fiore S; Praestgaard A; Bykerk V; Bingham CO; Charles-Schoeman C; Burmester G
    Arthritis Res Ther; 2022 Aug; 24(1):207. PubMed ID: 36008838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.
    Boyapati A; Msihid J; Fiore S; van Adelsberg J; Graham NM; Hamilton JD
    Arthritis Res Ther; 2016 Oct; 18(1):225. PubMed ID: 27716324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials.
    Xiang H; Liu L; Gao Y; Ahene A; Collins H
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):899-910. PubMed ID: 34383128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis.
    Emery P; Rondon J; Parrino J; Lin Y; Pena-Rossi C; van Hoogstraten H; Graham NMH; Liu N; Paccaly A; Wu R; Spindler A
    Rheumatology (Oxford); 2019 May; 58(5):849-858. PubMed ID: 30590833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics, pharmacodynamics, and safety of single-dose subcutaneous sarilumab with or without methotrexate in Japanese patients with rheumatoid arthritis: Two single-dose studies.
    Ishii T; Sato Y; Munakata Y; Kajiwara M; Takahashi Y; van Hoogstraten H; Xu C; Kato N; Takahashi T
    Mod Rheumatol; 2023 Mar; 33(2):279-291. PubMed ID: 35445719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
    Diao L; Hang Y; Othman AA; Nestorov I; Tran JQ
    Clin Pharmacokinet; 2016 Aug; 55(8):943-55. PubMed ID: 26873229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis.
    June RR; Olsen NJ
    Expert Opin Biol Ther; 2016 Oct; 16(10):1303-9. PubMed ID: 27464017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab.
    Strand V; Boklage SH; Kimura T; Joly F; Boyapati A; Msihid J
    Arthritis Res Ther; 2020 Oct; 22(1):250. PubMed ID: 33081825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses.
    Choy E; Freemantle N; Proudfoot C; Chen CI; Pollissard L; Kuznik A; Van Hoogstraten H; Mangan E; Carita P; Huynh TM
    RMD Open; 2019; 5(1):e000798. PubMed ID: 30886733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.